Watch this video on BIEL's ALLAY for period pain. After approval by the FDA for knee and foot, the ALLAY is next in line after general approval of the Actipatch. BIEL is now meeting with the FDA on May 9 and focusing on approving the Actipatch for back pain and muscles and joints pain. But, next in line is ALLAY. A new clinical trial on Allay was completed on April 1 and this is going to be huge on its own for $BIEL.
Back in 2009, the FDA did not approve it and it is taking 10 years for the FDA to consider. Watch and Enjoy
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.